ROWAN study overview
ROWAN will explore if there is a synergistic benefit of TheraSphere Y-90 Glass Microspheres with immunotherapy to improve response to cancer therapy in early and intermediate stage HCC patients.
ROWAN will explore if there is a synergistic benefit of TheraSphere Y-90 Glass Microspheres with immunotherapy to improve response to cancer therapy in early and intermediate stage HCC patients.
*CAUTION: In the U.S. TheraSphere is under an investigational device exemption for treatment of patients with metastatic colorectal cancer. The safety and effectiveness for this treatment has not been established.
TheraSphere is a registered trademark of Theragenics Corporation used under license by Biocompatibles UK Ltd., a wholly owned subsidiary of Boston Scientific Corporation.